{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:47Z","timestamp":1761897047821,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40262-019-00793-x","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T02:02:29Z","timestamp":1564452149000},"page":"51-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes"],"prefix":"10.1007","volume":"59","author":[{"given":"Lisa Alina","family":"Kneller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-6423","authenticated-orcid":false,"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"793_CR1","unstructured":"World Health Organization. Schizophrenia\u2014fact sheet. 2018. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia. Accessed 14 Aug 2018."},{"key":"793_CR2","unstructured":"World Health Organization. The world health report 2001: mental health: new understanding, new hope. 2018. http:\/\/www.who.int\/whr\/2001\/en\/whr01_en.pdf. Accessed 14 Aug 2018."},{"issue":"2","key":"793_CR3","first-page":"685","volume":"244","author":"PA Janssen","year":"1988","unstructured":"Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244(2):685\u201393.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9896","key":"793_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"2","key":"793_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JCP.0000000000000464","volume":"36","author":"Q-J Bo","year":"2016","unstructured":"Bo Q-J, Li X-B, Wang Z-M, Li A-N, Ma X, Wang C-Y. Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study. J Clin Psychopharmacol. 2016;36(2):125\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 4","key":"793_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/PL00014189","volume":"249","author":"S Kasper","year":"1999","unstructured":"Kasper S, Tauscher J, K\u00fcfferle B, Barnas C, Pezawas L, Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 4):83\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"793_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.1993.146","volume":"54","author":"ML Huang","year":"1993","unstructured":"Huang ML, van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54(3):257\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"793_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/PL00005334","volume":"359","author":"J Fang","year":"1999","unstructured":"Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(2):147\u201351.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"793_CR9","first-page":"1263","volume":"29","author":"N Yasui-Furukori","year":"2001","unstructured":"Yasui-Furukori N, Hidestrand M, Spina E, Facciol\u00e1 G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29(10):1263\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"793_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4088\/JCP.v60n0709","volume":"60","author":"Jayme A. Bork","year":"1999","unstructured":"Bork JA, Rogers T, Wedlund PJ, Leon Jd. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60(7):469\u201376.","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"793_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","volume":"22","author":"E Spina","year":"2000","unstructured":"Spina E, Avenoso A, Facciol\u00e0 G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22(4):481\u20135.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"793_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27\u201335.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"793_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","volume":"28","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, de Leon J, Haen E, et al. Pharmacokinetics of risperidone in different application forms\u2014comparing long-acting injectable and oral formulations. Eur Neuropsychopharmacol. 2018;28(1):130\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u201302","key":"793_CR14","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"793_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","volume":"21","author":"AE Balant-Gorgia","year":"1999","unstructured":"Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit. 1999;21(1):105\u201315.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"793_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-2007-979308","volume":"31","author":"M Aravagiri","year":"1998","unstructured":"Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998;31(3):102\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"793_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689\u2013723.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"793_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02246543","volume":"122","author":"E Snoeck","year":"1995","unstructured":"Snoeck E, van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology. 1995;122(3):223\u20139.","journal-title":"Psychopharmacology"},{"key":"793_CR19","first-page":"131","volume":"9","author":"A Puangpetch","year":"2016","unstructured":"Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C. CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med. 2016;9:131\u201347.","journal-title":"Pharmgenomics Pers Med"},{"issue":"2","key":"793_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2):234\u201342.","journal-title":"Clin Pharmacol Ther"},{"volume-title":"Applying pharmacogenomics in therapeutics","year":"2016","key":"793_CR21","unstructured":"Xie H-G, Feng X, editors. Applying pharmacogenomics in therapeutics. Boca Raton: CRC Press; 2016."},{"issue":"1","key":"793_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.v66n0103","volume":"66","author":"J de Leon","year":"2005","unstructured":"de Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15\u201327.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 11","key":"793_CR23","first-page":"12","volume":"57","author":"L Ereshefsky","year":"1996","unstructured":"Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(Suppl 11):12\u201325.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"793_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1559-0275-8-12","volume":"8","author":"AH Wu","year":"2011","unstructured":"Wu AH. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics. 2011;8(1):12.","journal-title":"Clin Proteomics"},{"issue":"6","key":"793_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/FTD.0b013e3181896afc","volume":"30","author":"N Bozina","year":"2008","unstructured":"Bozina N, Jovanovi\u0107 N, Lovri\u0107 M, Medved V. Clinical significance of a CYP2D6 poor metabolizer\u2013a patient with schizophrenia on risperidone treatment. Ther Drug Monit. 2008;30(6):748\u201351.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"793_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl M-L, Dal\u00e9n P, Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111\u201322.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"793_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","volume":"20","author":"OV Olesen","year":"1998","unstructured":"Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20(4):380\u20134.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"793_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s002130051171","volume":"147","author":"MG Scordo","year":"1999","unstructured":"Scordo MG, Spina E, Facciol\u00e0 G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147(3):300\u20135.","journal-title":"Psychopharmacology"},{"issue":"9","key":"793_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s002280100372","volume":"57","author":"HK Roh","year":"2001","unstructured":"Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57(9):671\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"793_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","volume":"25","author":"K Mihara","year":"2003","unstructured":"Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25(3):287\u201393.","journal-title":"Ther Drug Monit"},{"key":"793_CR31","unstructured":"Open Systems Pharmacology. Software PK-Sim\u00ae: 7.3.0. 2018. https:\/\/github.com\/Open-Systems-Pharmacology\/Suite\/releases\/tag\/v7.3.0. Accessed 7 Sep 2018."},{"issue":"4","key":"793_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","volume":"1","author":"S Willmann","year":"2003","unstructured":"Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim\u00ae: a physiologically based pharmacokinetic \u2018whole-body\u2019 model. BIOSILICO. 2003;1(4):121\u20134.","journal-title":"BIOSILICO"},{"key":"793_CR33","unstructured":"Open Systems Pharmacology. PK-Sim\u00ae software manual. http:\/\/www.open-systems-pharmacology.org. Accessed 7 Sep 2018."},{"issue":"3","key":"793_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401\u201331.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"793_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fphys.2011.00004","volume":"2","author":"T Eissing","year":"2011","unstructured":"Eissing T, Kuepfer L, Becker C, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2:4.","journal-title":"Front Physiol"},{"issue":"10","key":"793_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5(10):516\u201331.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"793_CR37","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","volume":"30","author":"J Novalbos","year":"2010","unstructured":"Novalbos J, L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Gallego-Sand\u00edn S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010;30(5):504\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"793_CR38","unstructured":"Janssen Pharmaceutical Ltd. Product information Risperdal\u00ae (risperidone) tablets. FDA Accessdata. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020272s042,020588s030,021444s016,021346s010lbl.pdf. Accessed 7 Sep 2018."},{"issue":"6","key":"793_CR39","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2174\/138920010791636202","volume":"11","author":"JJ Sheehan","year":"2010","unstructured":"Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516\u201325.","journal-title":"Curr Drug Metab."},{"issue":"5","key":"793_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","volume":"46","author":"MC Mauri","year":"2007","unstructured":"Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, de Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46(5):359\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"793_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hup.720","volume":"20","author":"TB Ejsing","year":"2005","unstructured":"Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol. 2005;20(7):493\u2013500.","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"793_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259\u201376.","journal-title":"J Pharm Sci"},{"issue":"6","key":"793_CR43","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238\u201357.","journal-title":"J Pharm Sci"},{"issue":"5","key":"793_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.2420","volume":"29","author":"T Cabaleiro","year":"2014","unstructured":"Cabaleiro T, Ochoa D, L\u00f3pez-Rodr\u00edguez R, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014;29(5):459\u201369.","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"793_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72(1):76\u201389.","journal-title":"Clin Pharmacol Ther"},{"issue":"D1","key":"793_CR46","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"David S Wishart","year":"2017","unstructured":"Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2017;46(D1):D1074\u2013D1082.","journal-title":"Nucleic Acids Research"},{"issue":"3","key":"793_CR47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"Vellarkad N. Viswanadhan","year":"1989","unstructured":"Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci. 1989;29(3):163\u201372.","journal-title":"Journal of Chemical Information and Modeling"},{"issue":"4","key":"793_CR48","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/BF02244986","volume":"114","author":"G Mannens","year":"1994","unstructured":"Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology. 1994;114(4):566\u201372.","journal-title":"Psychopharmacology"},{"issue":"1","key":"793_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/S1092852900020022","volume":"14","author":"J de Leon","year":"2009","unstructured":"de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14(1):19\u201334.","journal-title":"CNS Spectr"},{"issue":"Suppl","key":"793_CR50","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):13\u20137.","journal-title":"J Clin Psychiatry"},{"key":"793_CR51","unstructured":"Janssen-Cilag GmbH. Fachinformation RISPERDAL\u00ae 0.5 mg, Filmtabletten. 2018. https:\/\/www.gelbe-liste.de\/produkte\/RISPERDAL-0-5-mg-Filmtabletten_355913. Accessed 10 Aug 2018."},{"issue":"3","key":"793_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","volume":"27","author":"Zhi-ling ZHOU","year":"2006","unstructured":"Zhou Z-l, Li X, Peng H-y, et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 2006;27(3):381\u20136.","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"793_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"793_CR54","unstructured":"European Medicines Agency. Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation: draft. London. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500211315.pdf. Accessed 24 Aug 2018."},{"key":"793_CR55","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008. ISBN 3-900051-07-0. http:\/\/www.R-project.org."},{"issue":"1","key":"793_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","volume":"122","author":"E Spina","year":"2015","unstructured":"Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122(1):5\u201328.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"793_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","volume":"47","author":"J de Leon","year":"2006","unstructured":"de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75\u201385.","journal-title":"Psychosomatics"},{"issue":"3","key":"793_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/tpj.2010.91","volume":"12","author":"S Mas","year":"2012","unstructured":"Mas S, Gass\u00f2 P, Alvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. 2012;12(3):255\u20139.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"793_CR59","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442\u201373.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"793_CR60","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4088\/JCP.v62n0411","volume":"62","author":"R Williams","year":"2001","unstructured":"Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 2001;62(4):282\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"793_CR61","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","volume":"10","author":"G Schoretsanitis","year":"2017","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965\u201381.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"793_CR62","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P","volume":"90","author":"P Poulin","year":"2001","unstructured":"Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci. 2001;90(4):436\u201347.","journal-title":"J Pharm Sci"},{"issue":"1","key":"793_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","volume":"89","author":"P Poulin","year":"2000","unstructured":"Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci. 2000;89(1):16\u201335.","journal-title":"J Pharm Sci"},{"key":"793_CR64","unstructured":"Deutscher Apotheker Verlag. Monographien H - Z. 9. Ausgabe, Grundwerk 2017. Europ\u00e4isches Arzneibuch, 9.2017, Band 3. Stuttgart: Deutscher Apotheker Verlag; Govi-Verlag\u2014Pharmazeutischer Verlag. 2017."},{"issue":"2","key":"793_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/hup.2516","volume":"31","author":"M Okubo","year":"2016","unstructured":"Okubo M, Morita S, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5. Hum Psychopharmacol. 2016;31(2):93\u2013102.","journal-title":"Hum Psychopharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-019-00793-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T13:04:58Z","timestamp":1650459898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-019-00793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00793-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"30 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lisa Alina Kneller, Francisco Abad-Santos, and Georg Hempel have no potential conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}